These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37680248)

  • 1. Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study.
    Desai A; Hashash JG; Kochhar GS; Farraye FA
    Crohns Colitis 360; 2023 Jul; 5(3):otad047. PubMed ID: 37680248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis.
    Najjar-Debbiny R; Gronich N; Weber G; Stein N; Saliba W
    Clin Infect Dis; 2023 Mar; 76(6):1067-1073. PubMed ID: 36310534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
    Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
    Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
    Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
    Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
    Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
    Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.
    Sciascia S; Rilat MLA; Fenoglio R; Foddai SG; Radin M; Cecchi I; Cinnirella G; Crosasso P; Guidetti MG; Barinotti A; Baldovino S; Menegatti E; Roccatello D
    Clin Kidney J; 2023 Sep; 16(9):1465-1468. PubMed ID: 37664578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Evusheld safety and efficacy in multiple sclerosis patients.
    Liu EN; Real M; Yang JH; Fair A; Whitmire N; Perez A; Wilder C; Rosengren S; Kinkel RP; Graves JS
    Mult Scler Relat Disord; 2024 Aug; 88():105733. PubMed ID: 38901372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.
    Stastna D; Vachova M; Dusek P; Fistravec G; Drahota J; Menkyova I; Varju E; Horakova D; Kubala Havrdova E; Nytrova P
    Mult Scler Relat Disord; 2024 May; 85():105523. PubMed ID: 38452649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients.
    Marti-Pastor M; Bou-Monterde R; Ciancotti-Oliver L; Alcover-Pons M; Amorós Cantero A; Sánchez-Lopezosa R; Montañana-Rosell N
    Med Clin (Barc); 2024 Sep; 163(6):275-280. PubMed ID: 38937218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.
    Nassar MK; Sabry A; Elgamal M; Zeid Z; Abdellateif Abdelghany D; Tharwat S
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138212
    [No Abstract]   [Full Text] [Related]  

  • 12. Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients.
    Frączkiewicz J; Pawińska-Wąsikowska K; Szymbor K; Balwierz W; Skoczeń S; Czyżewski K; Kołtan S; Styczyński J; Małecka A; Irga-Jaworska N; Trelińska J; Młynarski W; Zając-Spychała O; Sobkowiak-Sobierajska A; Derwich K; Bal W; Chaber R; Książek A; Szczepański T; Zawitkowska J; Drabko K; Chodała-Grzywacz A; Karolczyk G; Kobierzycki C; Kałwak K
    J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610794
    [No Abstract]   [Full Text] [Related]  

  • 13. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
    Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
    Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
    Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
    Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tixagevimab + Cilgavimab: First Approval.
    Keam SJ
    Drugs; 2022 Jun; 82(9):1001-1010. PubMed ID: 35727563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab.
    Ocon AJ; Mustafa SS
    J Clin Rheumatol; 2023 Mar; 29(2):109-111. PubMed ID: 36126256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.
    Jakimovski D; Eckert SP; Mirmosayyeb O; Thapa S; Pennington P; Hojnacki D; Weinstock-Guttman B
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.
    Dluzynski D; Al-Shaikhly T; Paules CI; Henao MP
    J Allergy Clin Immunol Glob; 2024 Aug; 3(3):100293. PubMed ID: 39071730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea.
    Jo Y; Kim SB; Jung J
    J Korean Med Sci; 2023 Aug; 38(32):e250. PubMed ID: 37582500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.